A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of IBI362 in Chinese Adolescents With Obesity or Overweight（GLORY-YOUNG）
Innovent Biologics (Suzhou) Co. Ltd.
180 participants
Dec 29, 2025
INTERVENTIONAL
Conditions
Summary
The study is designed to assess the efficacy and safety of multiple doses of IBI362 in Chinese adolescent subjects with obesity or overweight. It plans to enroll 180 adolescents (aged ≥12 and \<18 years) who have failed to achieve a 5 kg weight reduction after at least 12 weeks of dietary and exercise intervention.
Eligibility
Inclusion Criteria3
- Male or female participants aged ≥12 years and <18 years at the time of signing the informed consent/assent form.
- BMI at screening meeting the obesity criteria defined by "WS/T 586-2018 Screening for Overweight and Obesity in School-Age Children and Adolescents" or meeting overweight criteria plus at least one weight-related comorbidity: prediabetes, type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, or obstructive sleep apnea syndrome.
- Weight change <5 kg after ≥12 weeks of diet and exercise alone before screening (per self/parental report).
Exclusion Criteria3
- Prior diagnosis of type 1 diabetes.
- Pre-pubertal participants (Tanner Stage I).
- History of (or planned) bariatric surgery (except liposuction/abdominoplasty or acupuncture for weight loss performed >1 year before screening).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Placebo SA.QW
IBI362 SA.QW
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07255209